27. December 2022 | Corporate News

Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents

Press release

Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), announces that the United States Patent and Trademark Office has granted the patent US11510859 covering the Marinosolv technology and its solubility enhancing properties. Specifically, the patent protects Marinosolv as a method for improving the aqueous solubility of drugs that are hardly soluble in aqueous formulations. By increasing solubility, the Marinosolv technology can significantly improve existing and development-stage drugs for the treatment of a multitude of diseases.

The full press release is available as download here: 

Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents
(61 KB)